ARTICLE | Clinical News
ASF-1057: Phase IIb started
October 30, 2006 8:00 AM UTC
Astion began a double-blind, placebo-controlled, French Phase IIb trial (Study 204) in 104 patients. Subjects will receive 1 of 3 doses of ASF-1057 or placebo once-daily for 3 weeks. ...